As the coro­n­avirus pan­dem­ic con­tin­ues to rat­tle the world, bio­phar­ma braces for a few new shocks to the sys­tem

While Pres­i­dent Don­ald Trump was ready­ing a trav­el ban to Eu­rope, the NBA was sus­pend­ing the rest of its sea­son and movie star Tom Han­ks an­nounced that he had been in­fect­ed by coro­n­avirus, the glob­al pan­dem­ic now spread­ing through the US con­tin­ued to send shock waves through the bio­phar­ma in­dus­try.

On Wednes­day came news of the lat­est up­date on coro­n­avirus cas­es re­lat­ed to the Bio­gen con­ta­gion, which trig­gered a grow­ing clus­ter of cas­es in Mass­a­chu­setts. Two US Sen­a­tors from both ma­jor par­ties are ad­vo­cat­ing a $100 mil­lion plan to bring phar­ma man­u­fac­tur­ing back to the US. The FDA’s de­ci­sion to can­cel most meet­ings has the an­a­lyst core work­ing over­time try­ing to gauge the im­pact on ap­proval sched­ules. Genen­tech was one of the lat­est of the big play­ers to deal with coro­n­avirus on cam­pus. And AS­CO is ex­plor­ing its op­tion if they take their huge an­nu­al meet­ing on­line.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.